Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

PURPOSE: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Demetri, George D., De Braud, Filippo, Drilon, Alexander, Siena, Salvatore, Patel, Manish R., Cho, Byoung Chul, Liu, Stephen V., Ahn, Myung-Ju, Chiu, Chao-Hua, Lin, Jessica J., Goto, Koichi, Lee, Jeeyun, Bazhenova, Lyudmila, John, Thomas, Fakih, Marwan, Chawla, Sant P., Dziadziuszko, Rafal, Seto, Takashi, Heinzmann, Sebastian, Pitcher, Bethany, Chen, David, Wilson, Timothy R., Rolfo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365368/
https://www.ncbi.nlm.nih.gov/pubmed/35144967
http://dx.doi.org/10.1158/1078-0432.CCR-21-3597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365368/
https://www.ncbi.nlm.nih.gov/pubmed/35144967
http://dx.doi.org/10.1158/1078-0432.CCR-21-3597

Ejemplares similares